Jesus Berdeja, MD | Authors


JNJ-4528 Remains Under Evaluation for Relapsed/Refractory Multiple Myeloma

June 03, 2020

Jesus Berdeja, MD, discusses the next steps for the chimeric antigen receptor T-cell therapy JNJ-4528 following the data from the phase 1b portion of the CARTITUDE-1 trial in patients with relapsed/refractory multiple myeloma.

Dr. Berdeja Discusses Results for bb2121 in Multiple Myeloma

December 12, 2017

Jesus Berdeja, MD, Director of Multiple Myeloma Research, Sarah Cannon Research Institute, discusses results of a study that explored bb2121, an anti-BCMA CAR T cell therapy, in heavily pretreated patients with relapsed/refractory multiple myeloma during the 2017 ASH Annual Meeting.